Ivory Is Big Business for One of Japan’s Largest Online Markets, but Is It Regulated?
In just four weeks in May and June of 2017 nearly 10,000 ivory items were sold on Yahoo Auction, one of Japan's largest e-commerce platforms.
Browsing Tag
Pacific Standard Partners
1673 posts
The False Choice Behind Legal Immigration
A nation that treats family visas as a sentimental luxury will lose talent to countries that are smart enough to have more sensible immigration policies.
Affirmative Action, Minority Students, and the Rich, White College Applicant
Asian Americans are indeed treated unfairly in admissions, but affirmative action is a convenient scapegoat for those who seek to pit minority groups against each other.
With Great Health Data Comes Great Potential for Bias
Are we creating health management systems that are responsive to differences, or ones that spit back content riddled with historical bias and discrimination?
Behind the Restorative Effects of Coral Gardening
The technique involves planting fragments of nursery-raised coral on reefs in the wild to replenish depleted colonies.
Generic Drug Prices Are Dropping, but Who Is This Really Benefiting?
It seems that overall drug spending is still on the rise because of the skyrocketing price of new, brand-name drugs.
The Deforestation Gangs of Colombia
In the country's southeast Guaviare department, harvested wood rots on the ground while gangs and drug traffickers take over the land for illegal mining and agriculture.
The Hidden Conflicts Within Trump’s Deregulation Teams
More possible conflicts of interest emerge among appointees as Democrats in Congress demand greater transparency from the White House.
One of Southeast Asia’s Conservation Areas Is Under Threat
Due to its size and location, the Tropical Rainforest Heritage of Sumatra in Indonesia is hailed as one of the largest conservation areas in Southeast Asia and the last habitat for many endangered animals.
Corporate Incentives Make Insurers Favor Pushing Brand-Name Drugs Over Cheaper Generics
Out of public view, corporations are cutting deals that give consumers little choice but to buy brand-name drugs—and sometimes pay more at the pharmacy counter than they would for generics.